Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40-billion-pound sales projection ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...

GSK said the forecasts were “inclusive of tariffs enacted thus far and indicated potential European tariffs' impact of 15 per ...

GSK lifted profit expectations for the year after the pharma group's sales were boosted by bumper demand for HIV and cancer ...

The outgoing pharma chief exec (pictured) said it was 'absolutely critical' that the government 'incentivise' investment in ...

Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

GSK PLC (GSK) reports robust sales growth and upgrades its full-year guidance, driven by strong performance in specialty medicines and oncology.

(Sharecast News) - Pharma giant GSK has received regulatory approval in China to expand the use of its Shingrix shingles vaccine, the company announced on Tuesday. Shingrix, which is currently ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in ...